Ray Dalio’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.6M | Sell |
22,724
-50,021
| -69% | -$38.3M | 0.08% | 179 |
|
|
2025
Q4 | $56.1M | Sell |
72,745
-162,636
| -69% | -$110M | 0.2% | 78 |
|
|
2025
Q3 | $132M | Buy |
235,381
+146,334
| +164% | +$82.7M | 0.52% | 36 |
|
|
2025
Q2 | $46.7M | Buy |
89,047
+68,056
| +324% | +$38M | 0.19% | 92 |
|
|
2025
Q1 | $13.3M | Buy |
20,991
+20,702
| +7,163% | +$14.2M | 0.06% | 225 |
|
|
2024
Q4 | $206K | Sell |
289
-268
| -48% | -$225K | ﹤0.01% | 678 |
|
|
2024
Q3 | $586K | Sell |
557
-4,797
| -90% | -$5.34M | ﹤0.01% | 674 |
|
|
2024
Q2 | $5.63M | Sell |
5,354
-55,792
| -91% | -$54.1M | 0.03% | 336 |
|
|
2024
Q1 | $58.9M | Sell |
61,146
-48,986
| -44% | -$46.6M | 0.3% | 67 |
|
|
2023
Q4 | $96.7M | Buy |
110,132
+49,383
| +81% | +$40.7M | 0.54% | 39 |
|
|
2023
Q3 | $50M | Sell |
60,749
-40,184
| -40% | -$31.6M | 0.3% | 66 |
|
|
2023
Q2 | $72.5M | Buy |
100,933
+36,035
| +56% | +$27.8M | 0.45% | 47 |
|
|
2023
Q1 | $53.3M | Buy |
64,898
+26,017
| +67% | +$19.6M | 0.33% | 62 |
|
|
2022
Q4 | $28.1M | Sell |
38,881
-18,596
| -32% | -$13.7M | 0.15% | 124 |
|
|
2022
Q3 | $39.6M | Sell |
57,477
-16,423
| -22% | -$10.3M | 0.2% | 97 |
|
|
2022
Q2 | $43.7M | Buy |
73,900
+68,448
| +1,255% | +$44.5M | 0.19% | 110 |
|
|
2022
Q1 | $3.81M | Sell |
5,452
-2,083
| -28% | -$1.32M | 0.02% | 532 |
|
|
2021
Q4 | $4.76M | Buy |
7,535
+113
| +2% | +$69.5K | 0.03% | 309 |
|
|
2021
Q3 | $4.49M | Sell |
7,422
-5,263
| -41% | -$3.27M | 0.02% | 303 |
|
|
2021
Q2 | $7.08M | Buy |
+12,685
| New | +$6.43M | 0.05% | 274 |
|
|
2019
Q4 | – | Sell |
-61,705
| Closed | -$17.1M | – | 558 |
|
|
2019
Q3 | $17.1M | Buy |
61,705
+59,330
| +2,498% | +$17.6M | 0.15% | 67 |
|
|
2019
Q2 | $743K | Buy |
+2,375
| New | +$791K | 0.01% | 245 |
|
|
2019
Q1 | – | Sell |
-4,842
| Closed | -$1.81M | – | 467 |
|
|
2018
Q4 | $1.81M | Sell |
4,842
-7,930
| -62% | -$2.9M | 0.02% | 254 |
|
|
2018
Q3 | $5.16M | Buy |
12,772
+1,273
| +11% | +$484K | 0.05% | 125 |
|
|
2018
Q2 | $3.97M | Sell |
11,499
-10,373
| -47% | -$3.24M | 0.04% | 153 |
|
|
2018
Q1 | $7.53M | Buy |
+21,872
| New | +$7.61M | 0.07% | 84 |
|
|
2017
Q4 | – | Sell |
-25,700
| Closed | -$11.5M | – | 312 |
|
|
2017
Q3 | $11.5M | Buy |
+25,700
| New | +$12.2M | 0.08% | 67 |
|
|
2016
Q2 | – | Sell |
-900
| Closed | -$324K | – | 370 |
|
|
2016
Q1 | $324K | Buy |
+900
| New | +$371K | ﹤0.01% | 250 |
|
|
2015
Q4 | – | Sell |
-1,800
| Closed | -$837K | – | 380 |
|
|
2015
Q3 | $837K | Buy |
1,800
+1,000
| +125% | +$537K | 0.01% | 251 |
|
|
2015
Q2 | $408K | Buy |
+800
| New | +$390K | ﹤0.01% | 281 |
|
|
2015
Q1 | – | Sell |
-11,800
| Closed | -$4.84M | – | 386 |
|
|
2014
Q4 | $4.84M | Buy |
11,800
+10,200
| +638% | +$4.01M | 0.04% | 109 |
|
|
2014
Q3 | $577K | Sell |
1,600
-16,800
| -91% | -$5.63M | ﹤0.01% | 267 |
|
|
2014
Q2 | $5.2M | Buy |
+18,400
| New | +$5.45M | 0.04% | 102 |
|
|
2013
Q3 | – | Sell |
-4,100
| Closed | -$922K | – | 391 |
|
|
2013
Q2 | $922K | Buy |
+4,100
| New | +$955K | 0.01% | 198 |
|
Other funds holding REGN
VCM
N
Ray Dalio's REGN Position: Q1 2026 in Review
Ray Dalio reduced its Regeneron Pharmaceuticals (REGN) stake by 69% in Q1 2026, selling an estimated $38.3M and leaving 22,724 shares worth $17.6M. The position accounts for 0.08% of the portfolio, ranked #179.
Ray Dalio first reported a position in REGN in Q2 2013 and has held it in 34 quarters since. The position peaked at $132M in Q3 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Ray Dalio held 22,724 shares of Regeneron Pharmaceuticals worth $17.6M as of Q1 2026.
- Ray Dalio sold 50,021 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $38.3M.
- Regeneron Pharmaceuticals made up 0.08% of Ray Dalio's portfolio in Q1 2026, its #179 holding.
- Ray Dalio first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
- Ray Dalio's Regeneron Pharmaceuticals position peaked at $132M in Q3 2025.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.